Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

Table 1 Characteristics of the NSCLC primary tumours tested

Tumour #	Gender, age at excision	Site	Clinical diagnosis of specimen	AJCC/UICC stage group	Medications	Genetic analysis
1	F, 79	Lung	Squamous cell carcinoma of the lung	IA		SNPs: rs2075607 (LKB1), rs1042522 (TP53)
2	M, 57	Lung	Adenocarcinoma of the lung	IIB	Combivent	nd
					Lovenox
					Advair
3	M, 61	Abdominal wall	Metastatic neoplasm of the abdominal wall	IV	Carboplatin	Highly aberrant copy number variations across genome
					Paclitaxel	Point mutations: KRas G12D, TP53 V157F
					Alimta	SNPs: rs2075607 (LKB1)
					Tarceva
					Gemcitabine

ISSN: 1476-4598